Tokyo, Feb. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000056743) titled 'The effect of beta-hydroxybutyrate (D-BHB)-containing protein intake on physical and mental fatigue in healthy adult' on Feb. 28.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Double blind -all involved are blinded
Control - Placebo
Primary Sponsor:
Institute - User Life Science Co., Ltd.
Condition:
Condition - Healthy adult
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the effect of beta-hydroxybutyrate (D-BHB) intake on physical and mental health in healthy adult
Basic objectives2 - Efficacy
Intervention:
Interventions/Control_1 - To dissolve D-BHB-containing protein (D-BHB 2 g/day) in 200 ml of water and intake it for 4 weeks (28 days)
Interventions/Control_2 - To dissolve the placebo protein not containing D-BHB in 200 ml of water and intake it for 4 weeks (28 days)
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - (1) persons who is generally judged as healthy
(2) Persons who can give voluntary written consent to participate in the present trial
(3) Persons who are aware of their physical and mental fatigue and stress
Key exclusion criteria - (1) persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study
(2) persons who have changed their habitats to take supplements within past 4 weeks.
(3) Persons who work in night shift or in day and night shift
(4) persons who have been treated their illness or prevention in a clinic at their informed consent
(5) persons with their medical histories as follows: serious diseases of sugar metabolism, lipid metabolism, hepatic function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system
(6) persons with the medical histories of alcoholism or drug dependence
(7) persons who might be developed allergic reaction to foods
(8) Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period
(9) persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device)
(10) persons who will not be judged suitable to the participants by the investigator
Target Size - 40
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2024 Year 12 Month 20 Day
Date of IRB - 2024 Year 03 Month 06 Day
Anticipated trial start date - 2025 Year 01 Month 17 Day
Last follow-up date - 2025 Year 02 Month 28 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064847
Disclaimer: Curated by HT Syndication.